



Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021

November 8, 2021

SAN DIEGO--(BUSINESS WIRE)--Nov. 8, 2021-- [Biocept, Inc.](#) (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and nine months ended September 30, 2021 after the market closes on Monday, November 15, 2021. The Company will host an investor conference call to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Date/Time: Monday, November 15, 4:30 p.m. ET / 1:30 p.m. PT

Pre-Registration: Participants can pre-register for the conference call [here](#).

Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

Dial In: Those who choose not to pre-register can access the live conference call by dialing the following and requesting the Biocept call:

U.S. Callers: 855-656-0927

Canadian Callers: 855-669-9657

Other International Callers: 412-902-4109

A live webcast of the call will be available at <https://ir.biocept.com/>. The webcast will be archived for 90 days.

A replay of the conference call will be available for 48 hours following the conclusion of the call by dialing (877) 344-7529 for domestic callers, (855) 669-9658 for Canadian callers, or (412) 317-0088 for other international callers, and entering the replay access code 10161580.

About Biocept

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector™ technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on [Facebook](#), [LinkedIn](#) and [Twitter](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20211108005056/en/): <https://www.businesswire.com/news/home/20211108005056/en/>

LHA Investor Relations

Jody Cain
Jcain@lhai.com
310-691-7100

Source: Biocept, Inc.